Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Quantifying Duration of Proteinuria Remission and Association with Clinical Outcome in IgA Nephropathy (CROSBI ID 310329)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

(International IgA Nephropathy Network) Canney, Mark ; Barbour, Sean J. ; Zheng, Yuyan ; Coppo, Rosanna ; Zhang, Hong ; Liu, Zhi-Hong ; Matsuzaki, Keiichi ; Suzuki, Yusuke ; Katafuchi, Ritsuko ; Reich, Heather N. et al. Quantifying Duration of Proteinuria Remission and Association with Clinical Outcome in IgA Nephropathy // Journal of the American Society of Nephrology, 32 (2020), 2; 436-447. doi: 10.1681/asn.2020030349

Podaci o odgovornosti

Canney, Mark ; Barbour, Sean J. ; Zheng, Yuyan ; Coppo, Rosanna ; Zhang, Hong ; Liu, Zhi-Hong ; Matsuzaki, Keiichi ; Suzuki, Yusuke ; Katafuchi, Ritsuko ; Reich, Heather N. ; Cattran, Daniel ; for the International IgA Nephropathy Network

International IgA Nephropathy Network

engleski

Quantifying Duration of Proteinuria Remission and Association with Clinical Outcome in IgA Nephropathy

Background: On the basis of findings of observational studies and a meta-analysis, proteinuria reduction has been proposed as a surrogate outcome in IgA nephropathy. How long a reduction in proteinuria needs to be maintained to mitigate the long-term risk of disease progression is unknown. Methods: In this retrospective multiethnic cohort of adult patients with IgA nephropathy, we defined proteinuria remission as a ≥25% reduction in proteinuria from the peak value after biopsy, and an absolute reduction in proteinuria to <1 g/d. The exposure of interest was the total duration of first remission, treated as a time-varying covariate using longitudinal proteinuria measurements. We used time-dependent Cox proportional hazards regression models to quantify the association between the duration of remission and the primary outcome (ESKD or a 50% reduction in eGFR). Results: During a median follow-up of 3.9 years, 274 of 1864 patients (14.7%) experienced the primary outcome. The relationship between duration of proteinuria remission and outcome was nonlinear. Each 3 months in sustained remission up to approximately 4 years was associated with an additional 9% reduction in the risk of disease progression (hazard ratio [HR], 0.91 ; 95% confidence interval [95% CI], 0.89 to 0.93). Thereafter, each additional 3 months in remission was associated with a smaller, nonsignificant risk reduction (HR, 0.99 ; 95% CI, 0.96 to 1.03). These findings were robust to multivariable adjustment and consistent across clinical and histologic subgroups. Conclusions: Our findings support the use of proteinuria as a surrogate outcome in IgA nephropathy, but additionally demonstrate the value of quantifying the duration of proteinuria remission when estimating the risk of hard clinical endpoints.

IgA nephropathy ; end stage kidney disease ; epidemiology and outcomes ; glomerular disease ; proteinuria ; renal function decline ; renal pathology.

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

32 (2)

2020.

436-447

objavljeno

1046-6673

1533-3450

10.1681/asn.2020030349

Povezanost rada

Kliničke medicinske znanosti

Poveznice
Indeksiranost